{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 49,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a process diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/30",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.96,
        "x": 0.02,
        "y": 0.58
      },
      "kind": "callout",
      "text": "Scientific Basis: IMX-110 turns “cold” tumors “hot” in genetic (KPC) mouse models of pancreatic cancer",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83a6cd10-a54b-4f72-a44a-b14407665c9e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.96,
        "x": 0.02,
        "y": 0.73
      },
      "kind": "diagram",
      "text": "Mechanism of action: Eliminating T-regulatory cells -> enabling T-lymphocytes -> eliminating tumor vascularization.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f732566b-90ab-43f2-a7e7-d9b8eed6923e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.1,
        "y": 0.18
      },
      "kind": "image",
      "text": "BeiGene, ImmixBio, Novartis",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c1f9d8f-a2cd-417f-9b93-7a6f7763ce5a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.02,
        "y": 0.32
      },
      "kind": "list",
      "text": "Study Goal: Demonstrate potential for TSTx in combination therapies; Rapid IMX-110 expansion.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6036e41a-51f8-45c5-a5d1-25dab1062f82",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.35,
        "y": 0.32
      },
      "kind": "list",
      "text": "Combination Trial Design: IMX-110 + tislelizumab; 30 patient Phase 1b study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "880376bb-de10-4fe0-8282-eb21e20b6965",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.65,
        "y": 0.32
      },
      "kind": "list",
      "text": "Joint Alliance Committee: Coordinate clinical trial.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e084fd6f-309b-40ba-8ce3-407a0f707b61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.96,
        "x": 0.02,
        "y": 0.89
      },
      "kind": "paragraph",
      "text": "As of June 2021, in China, tislelizumab has already been approved or granted conditional approved in 5 cancer indications.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a11f2bf6-a31c-458c-8449-936c0e075786",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Trial and Supply Agreement with BeiGene for Tislelizumab (Anti-PD-1 mAb)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78f42084-1ced-471f-adc8-494077c59251",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "ed1e80c4-781b-461c-9289-1606a27586a0",
      "evidence": "The slide uses a sequence of images and text to explain the biological mechanism of action.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 36,
      "from": 22,
      "beatId": "5ee20672-1046-46ce-ad33-eb1d695994e8",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Discussion of market opportunity and clinical development plan",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 22,
      "name": "Pareto Focus",
      "slug": "50-pareto-focus",
      "bestFor": "Resource allocation, problem prioritization, efficiency improvements",
      "matchId": "24f91fa1-6eaa-45b1-9503-e96c3368cd2a",
      "evidence": "Presentation of market data and clinical development plan",
      "position": 1,
      "objective": "Focusing on key markets and opportunities",
      "structure": "The Full Distribution -> The Vital Few (20%) -> The Trivial Many (80%) -> Focus Recommendation",
      "confidence": 0.7,
      "description": "Show that 80% of results come from 20% of causes to drive prioritization"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}